Antares Pharma

Antares Pharma Attains FDA Acceptance of OTREXUP RA Drug Delivery System

The system is designed for subcutaneous delivery of rheumatoid arthritis treatments.

Antares Pharma, Inc. today announced that the New Drug Application (NDA) for OTREXUP, a potential new product for the subcutaneous delivery of methotrexate (MTX) using Medi-Jet technology, has been accepted by the U.S. Food and Drug Administration (FDA) indicating that the application is sufficiently complete to permit a substantive review. OTREXUP is being developed for self-administration of MTX to enhance the treatment of rheumatoid arthritis (RA), poly-articular-course juvenile RA and psoriasis.

No votes yet
Syndicate content